Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | GAA | P10253 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | RAD52 | P43351 | 2/20 | 0.68 |
| ▸ | GFER | P55789 | 2/20 | 0.68 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20251137 | 0.86 | MAPT (0.51) | MAPTGAAKDM4ESMN1; SMN2RAD52 | |
| SCHEMBL21066237 | 0.86 | GAA (0.59) | MAPTGAAKDM4ESMN1; SMN2RAD52 | |
| SCHEMBL14923982 | 0.85 | KMT2A (0.66) | MAPTGAAKDM4ESMN1; SMN2RAD52 | |
| SCHEMBL23866004 | 0.84 | MAPT (0.54) | MAPTGAAKDM4ESMN1; SMN2RAD52 | |
| SCHEMBL21450680 | 0.82 | MAPT (0.59) | MAPTGAAKDM4ESMN1; SMN2SIGMAR1 | |
| SCHEMBL27741254 | 0.82 | SMN1; SMN2 (0.54) | MAPTGAAKDM4ESMN1; SMN2RAD52 | |
| SCHEMBL27741257 | 0.82 | GAA (0.54) | MAPTGAAKDM4ESMN1; SMN2RAD52 | |
| SCHEMBL6152136 | 0.81 | MAPT (1.00) | MAPTGAAKDM4ESMN1; SMN2RAD52 | |
| SCHEMBL158007 | 0.81 | MAPT (1.00) | MAPTGAAKDM4ESMN1; SMN2RAD52 | |
| SCHEMBL10891766 | 0.81 | KMT2A (0.71) | MAPTGAAKDM4ESMN1; SMN2RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| EP-4169919-A1 | PYRAZOLO[3,4-D]PYRIMIDINE-3-KETONE DERIVATIVE AS WEE-1 INHIBITOR | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
| US-20220305016-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-09-29 | — | — | US | disclosed |
| US-20220168313-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-06-02 | — | — | US | disclosed |
| US-20220162229-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-05-26 | — | — | US | disclosed |
| US-20220133736-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-05-05 | — | — | US | disclosed |
| US-9345719-B2 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2016-05-24 | — | — | US | disclosed |
| US-20150299185-A1 | NOVEL IMIDAZOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR | HANMI PHARM. CO., LTD. (KR) | 2015-10-22 | — | — | US | disclosed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-8957065-B2 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD (KR) | 2015-02-17 | — | — | US | disclosed |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2015-02-12 | — | — | US | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060113-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD. (KR) | 2013-05-09 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299185-A1 | NOVEL IMIDAZOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR | LCK, ABL1, TYK2 | MAPT 2021/4885GAA 2133/4885KDM4E 937/4885 |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | MAPT 4661/4885GAA 447/4885KDM4E 2287/4885 |
| US-20220133736-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | SIK2, SIK1, SIK3 | MAPT 3248/4885GAA 1221/4885KDM4E 1681/4885 |
| US-20220162229-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | MAPT 4445/4885GAA 1874/4885KDM4E 795/4885 |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | MAPT 1168/4885GAA 172/4885KDM4E 4157/4885 |
| US-20220168313-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, VHL | MAPT 3958/4885GAA 987/4885KDM4E 1729/4885 |
| US-20220305016-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | SOST, SIK2, SIK1 | MAPT 1864/4885GAA 3066/4885KDM4E 1613/4885 |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | MAPT 3529/4885GAA 1274/4885KDM4E 2606/4885 |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | JAK3, JAK1, JAK2 | MAPT 3409/4885GAA 3514/4885KDM4E 1182/4885 |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | MAPT 2825/4885GAA 1774/4885KDM4E 1746/4885 |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | MAPT 2825/4885GAA 1774/4885KDM4E 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.